Home > Boards > US Listed > Biotechs > Chembio Diagnostics (CEMI)

Research and Development

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
XenaLives Member Profile
Member Level 
Followed By 367
Posts 49,200
Boards Moderated 29
Alias Born 09/20/01
160x600 placeholder
Chembio Diagnostics to Report Second Quarter 2021 Financial Results on August 5, 2021 GlobeNewswire Inc. - 7/22/2021 5:03:53 PM
Chembio Diagnostics gets $4M HIV test purchase order Seeking Alpha - 7/22/2021 1:03:18 PM
Chembio Diagnostics Receives $4 Million HIV Test Purchase Order Supported by The Global Fund GlobeNewswire Inc. - 7/22/2021 12:49:39 PM
NeuroMetrix stock joins Reddit-driven rally with 60% rise in Q2 revenue Seeking Alpha - 7/22/2021 10:00:48 AM
Chembio Diagnostics Bags $28.3M Oder for SARS-CoV-2 Antigen Tests from Brazil TipRanks - 7/22/2021 2:53:30 AM
Chembio surges on purchase order for COVID—19 antigen test from Brazil Seeking Alpha - 7/21/2021 8:12:26 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/21/2021 6:04:51 AM
Chembio Diagnostics Receives $28.3 Million Purchase Order from Bio-Manguinhos for DPP SARS-CoV-2 Antigen Tests in Brazil GlobeNewswire Inc. - 7/20/2021 10:56:14 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 7/19/2021 5:29:53 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/19/2021 5:14:54 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 7/12/2021 8:30:23 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/25/2021 5:21:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/10/2021 4:06:31 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 5/13/2021 9:27:27 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 5/13/2021 9:26:04 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 5/7/2021 6:10:06 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/6/2021 5:29:08 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/6/2021 4:30:47 PM
Chembio Diagnostics EPS beats by $0.10, beats on revenue Seeking Alpha - 5/6/2021 4:28:28 PM
Chembio Diagnostics Reports First Quarter 2021 Financial Results GlobeNewswire Inc. - 5/6/2021 4:05:00 PM
Amended Annual Report (10-k/a) Edgar (US Regulatory) - 4/30/2021 5:04:04 PM
Chembio Diagnostics to Report First Quarter 2021 Financial Results on May 6, 2021 GlobeNewswire Inc. - 4/22/2021 8:00:00 AM
Chembio announces U.S. launch of point-of-care-test to differentiate COVID-19 and Flu Seeking Alpha - 4/5/2021 10:28:43 AM
Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu GlobeNewswire Inc. - 4/1/2021 5:30:00 PM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 3/15/2021 6:33:37 AM
XenaLives Member Level  Thursday, 10/08/20 11:17:34 AM
Re: None
Post # of 698 

Research and Development
Chembio is committed to developing highly accurate, affordable, efficient point-of-care rapid test products to help prevent the spread of infectious diseases worldwide. Chembio has been a key OEM provider to global brands in the diagnostic industry for many years, and our experienced management and R&D teams are constantly looking for ways to provide innovative solutions for healthcare providers everywhere.

Currently, we partner with not only commercial organizations but also foundations, NGOs, and healthcare organizations to research and develop faster, more accurate rapid diagnostic devices. Our work focuses on the areas of HIV, STDs and TB, and other Infectious Diseases all which have established Chembio as one of the cutting-edge companies in the medical diagnostic assay industry.


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences